Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung.
Streptococcus pneumoniae infection is a leading cause of bacterial pneumonia, sepsis and meningitis and is associated with high morbidity and mortality. Type I interferon (IFN-I), whose contribution to antiviral and intracellular bacterial immunity is well established, is also elicited during pneumococcal infection, yet its functional significance is not well defined. Here, we show that IFN-I plays an important role in the host defense against pneumococci by counteracting the transmigration of bacteria from the lung to the blood. Mice that lack the type I interferon receptor (Ifnar1 (-/-)) or mice that were treated with a neutralizing antibody against the type I interferon receptor, exhibited enhanced development of bacteremia following intranasal pneumococcal infection, while maintaining comparable bacterial numbers in the lung. In turn, treatment of mice with IFNβ or IFN-I-inducing synthetic double stranded RNA (poly(I:C)), dramatically reduced the development of bacteremia following intranasal infection with S. pneumoniae. IFNβ treatment led to upregulation of tight junction proteins and downregulation of the pneumococcal uptake receptor, platelet activating factor receptor (PAF receptor). In accordance with these findings, IFN-I reduced pneumococcal cell invasion and transmigration across epithelial and endothelial layers, and Ifnar1 (-/-) mice showed overall enhanced lung permeability. As such, our data identify IFN-I as an important component of the host immune defense that regulates two possible mechanisms involved in pneumococcal invasion, i.e. PAF receptor-mediated transcytosis and tight junction-dependent pericellular migration, ultimately limiting progression from a site-restricted lung infection to invasive, lethal disease.
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Kim S
KS
LeMessurier
Hans
H
Häcker
Liying
L
Chi
Elaine
E
Tuomanen
Vanessa
V
Redecke
D000818:Animals; D016470:Bacteremia / Q000235:genetics / Q000378:metabolism; D015824:Blood-Air Barrier / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D001812:Blood-Brain Barrier / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D007370:Interferon Type I / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D018345:Mice, Knockout; D011018:Pneumonia, Pneumococcal / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D053633:Receptor, Interferon alpha-beta / Q000235:genetics / Q000378:metabolism; D013296:Streptococcus pneumoniae / Q000378:metabolism / Q000472:pathogenicity*
C508032:Ifnar1 protein, mouse; D007370:Interferon Type I; D053633:Receptor, Interferon alpha-beta